Northwest Biotherapeutics (NWBO) enters into agreements with long-time contract manufacturer Cognate Bioservices for the large-scale expansion of the manufacturing, storage, handling and distribution of Northwest's DCVax-L and DCVax-Direct products.
The company believes that the agreements will give it a head start ahead of Phase III testing of its therapies. Cognate has a "12-year track record of regulatory and operational success with two dozen different cell product trials," Northwest says.
The firm's DCVax products are personalized immune therapies for solid tumor cancers.
Shares are +7.4%. (PR)